PMID- 30641278
OWN - NLM
STAT- MEDLINE
DCOM- 20190823
LR  - 20190823
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 141
DP  - 2019 Mar
TI  - The signaling pathways that mediate the anti-cancer effects of caloric 
      restriction.
PG  - 512-520
LID - S1043-6618(18)31466-X [pii]
LID - 10.1016/j.phrs.2019.01.021 [doi]
AB  - Caloric restriction (CR) has been shown to promote longevity and ameliorate 
      aging-associated diseases, including cancer. Extensive research over recent 
      decades has revealed that CR reduces IGF-1/PI3K/AKT signaling and increases 
      sirtuin signaling. We recently found that CR also enhances ALDOA/DNA-PK/p53 
      signaling. In the present review, we summarize the molecular mechanisms 
      underlying the modulation of the IGF-1/PI3K/AKT pathway, sirtuin signaling, and 
      the ALDOA/DNA-PK/p53 pathway by CR. We also summarize the evidence concerning the 
      roles of these signaling pathways in carcinogenesis, and discuss how they are 
      regulated by CR. Finally, we discuss the crosstalk between these signaling 
      pathways.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Lu, Yiyi
AU  - Lu Y
AD  - Department of Dermato-Venereology, The First Affiliated Hospital of Wenzhou 
      Medical University, Wenzhou 325015, China.
FAU - Tao, Fengxing
AU  - Tao F
AD  - Department of Dermato-Venereology, The First Affiliated Hospital of Wenzhou 
      Medical University, Wenzhou 325015, China.
FAU - Zhou, Meng-Tao
AU  - Zhou MT
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou 325015, Zhejiang, China. Electronic address: zhoumengtao131@aliyun.com.
FAU - Tang, Kai-Fu
AU  - Tang KF
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou 325015, Zhejiang, China; Digestive Cancer Center, The First Affiliated 
      Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang, China. 
      Electronic address: tang_kaifu@wmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190112
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (DNA-Activated Protein Kinase)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.5.1.- (Sirtuins)
RN  - EC 4.1.2.13 (Fructose-Bisphosphate Aldolase)
MH  - Animals
MH  - *Caloric Restriction/methods
MH  - Carcinogenesis/*metabolism
MH  - DNA-Activated Protein Kinase/metabolism
MH  - Fructose-Bisphosphate Aldolase/metabolism
MH  - Humans
MH  - Insulin-Like Growth Factor I/metabolism
MH  - Neoplasms/*diet therapy/*metabolism/prevention & control
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - *Signal Transduction
MH  - Sirtuins/metabolism
MH  - Tumor Suppressor Protein p53/metabolism
OTO - NOTNLM
OT  - Caloric restriction
OT  - Cancer
OT  - DNA damage
OT  - Signaling pathway
EDAT- 2019/01/15 06:00
MHDA- 2019/08/24 06:00
CRDT- 2019/01/15 06:00
PHST- 2018/09/27 00:00 [received]
PHST- 2018/12/31 00:00 [revised]
PHST- 2019/01/11 00:00 [accepted]
PHST- 2019/01/15 06:00 [pubmed]
PHST- 2019/08/24 06:00 [medline]
PHST- 2019/01/15 06:00 [entrez]
AID - S1043-6618(18)31466-X [pii]
AID - 10.1016/j.phrs.2019.01.021 [doi]
PST - ppublish
SO  - Pharmacol Res. 2019 Mar;141:512-520. doi: 10.1016/j.phrs.2019.01.021. Epub 2019 
      Jan 12.